### Cervical Cancer Screening

<table>
<thead>
<tr>
<th>eMeasure Title</th>
<th>Cervical Cancer Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>eMeasure Identifier</td>
<td>124</td>
</tr>
<tr>
<td>eMeasure Version number</td>
<td>5.0.000</td>
</tr>
<tr>
<td>NQF Number</td>
<td>0032</td>
</tr>
<tr>
<td>GUID</td>
<td>42e7e489-790f-427a-a1a6-d6e807f65a6d</td>
</tr>
<tr>
<td>Measurement Period</td>
<td>January 1, 20XX through December 31, 20XX</td>
</tr>
<tr>
<td>Measure Steward</td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td>Measure Developer</td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td>Endorsed By</td>
<td>National Quality Forum</td>
</tr>
</tbody>
</table>
| Description             | Percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria:  
* Women age 21-64 who had cervical cytology performed every 3 years  
* Women age 30-64 who had cervical cytology/human papillomavirus (HPV) co-testing performed every 5 years |
| Copyright               | Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).  
The Measures are copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices). Commercial use is defined as the sale, licensing, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial use of the Measures requires a license agreement between the user and NCQA. NCQA is not responsible for any use of the Measures.  
(C) 2008-2016 National Committee for Quality Assurance. All Rights Reserved.  
Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications.  
| Measure Scoring         | Proportion                 |
| Measure Type            | Process                    |
| Stratification          | None                       |
| Risk Adjustment         | None                       |
| Rate Aggregation        | None                       |
| Rationale               | All women are at risk for cervical cancer, but it occurs most often in women over the age of 30. In 2015, approximately 12,900 women were diagnosed with cervical cancer in the U.S., resulting in an estimated 4,100 deaths (National Cancer Institute 2015). If pre-cancerous lesions are detected early by Pap tests and treated, the likelihood of survival is nearly 100 percent (American Cancer Society 2015). In 2013, women with no health insurance and recent immigrants were least likely to have a Pap test (American Cancer Society 2015). |
"The USPSTF recommends screening for cervical cancer in women aged 21 to 65 years with cytology (Papanicolaou smear) every 3 years or, for women aged 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and HPV testing every 5 years." (A recommendation)  
"The USPSTF recommends against screening for cervical cancer in women younger than age 21 years." (D recommendation)  
"The USPSTF recommends against screening for cervical cancer in women older than age 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer." (D recommendation)  
"The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and who do not have a history of a high-grade precancerous lesion (cervical intraepithelial neoplasia grade 2 or 3) or cervical cancer." (D recommendation). |
"The USPSTF recommends against screening for cervical cancer with HPV testing, alone or in combination with cytology, in women younger than age 30 years." (D recommendation)

**Improvement Notation**
Higher score equals better quality

**Reference**

**Reference**

**Reference**

**Definition**
None

**Guidance**
To ensure the measure is only looking for a cervical cytology test only after a woman turns 21 years of age, the youngest age in the initial population is 23

**Transmission Format**
TBD

**Initial Population**
Women 23-64 years of age with a visit during the measurement period

**Denominator**
Equals Initial Population

**Denominator Exclusions**
Women who had a hysterectomy with no residual cervix

**Numerator**
Women with one or more screenings for cervical cancer. Appropriate screenings are defined by any one of the following criteria:
- Cervical cytology performed during the measurement period or the two years prior to the measurement period for women who are at least 21 years old at the time of the test
- Cervical cytology/human papillomavirus (HPV) co-testing performed during the measurement period or the four years prior to the measurement period for women who are at least 30 years old at the time of the test

**Numerator Exclusions**
Not Applicable

**Denominator Exceptions**
None

**Supplemental Data Elements**
For every patient evaluated by this measure also identify payer, race, ethnicity and sex

---

**Table of Contents**

- Population Criteria
- Data Criteria (QDM Variables)
- Data Criteria (QDM Data Elements)
- Supplemental Data Elements
- Risk Adjustment Variables

---

**Population Criteria**

- **Initial Population =**
  - AND: Age>= 23 year(s) at: "Measurement Period"
  - AND: Age< 64 year(s) at: "Measurement Period"
  - AND: "Patient Characteristic Sex: Female"
  - AND: Union of:
    - "Encounter, Performed: Office Visit"
    - "Encounter, Performed: Face-to-Face Interaction"
    - "Encounter, Performed: Preventive Care Services - Established Office Visit, 18 and Up"
    - "Encounter, Performed: Preventive Care Services-Initial Office Visit, 18 and Up"
    - "Encounter, Performed: Home Healthcare Services"
    - during "Measurement Period"

- **Denominator =**
  - AND: Initial Population

- **Denominator Exclusions =**
  - OR: "Procedure, Performed: Hysterectomy with No Residual Cervix" ends before end of "Measurement Period"

- **Numerator =**
  - AND:
    - OR: "Laboratory Test,Performed: Pap Test (result)" < 3 year(s) ends before end of "Measurement Period"
Cervical Cancer Screening

**Data Criteria (QDM Variables)**

- None

**Data Criteria (QDM Data Elements)**

- "Encounter, Performed: Face-to-Face Interaction" using "Face-to-Face Interaction Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1048)"
- "Encounter, Performed: Office Visit" using "Office Visit Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1001)"
- "Encounter, Performed: Preventive Care Services - Established Office Visit, 18 and Up" using "Preventive Care Services - Established Office Visit, 18 and Up Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1025)"
- "Encounter, Performed: Preventive Care Services-Initial Office Visit, 18 and Up" using "Preventive Care Services-Initial Office Visit, 18 and Up Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1023)"
- "Laboratory Test, Performed: HPV Test" using "HPV Test Grouping Value Set (2.16.840.1.113883.3.464.1003.101.12.1059)"
- "Laboratory Test, Performed: Pap Test" using "Pap Test Grouping Value Set (2.16.840.1.113883.3.464.1003.108.12.1017)"
- "Patient Characteristic Sex: Female" using "Female AdministrativeGender Value Set (2.16.840.1.113883.3.560.100.2)"
- "Procedure, Performed: Hysterectomy with No Residual Cervix" using "Hysterectomy with No Residual Cervix Grouping Value Set (2.16.840.1.113883.3.464.1003.198.12.1014)"

**Supplemental Data Elements**

- "Patient Characteristic Ethnicity: Ethnicity" using "Ethnicity CDCREC Value Set (2.16.840.1.114222.4.11.837)"
- "Patient Characteristic Payer: Payer" using "Payer SOP Value Set (2.16.840.1.114222.4.11.3591)"
- "Patient Characteristic Race: Race" using "Race CDCREC Value Set (2.16.840.1.114222.4.11.836)"
- "Patient Characteristic Sex: ONC Administrative Sex" using "ONC Administrative Sex AdministrativeGender Value Set (2.16.840.1.113762.1.4.1)"

**Risk Adjustment Variables**

- None

| Measure Set | None |